Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: Results of an open-label multicenter study in Japan

Psychiatry and Clinical Neurosciences

Volumn 55, Issue 4, 2001, Pages 353-363

  Ishigooka, Jun ^a   Murasaki, Mitsukuni ^a   Miura, Sadanori ^a   Kamijima, Kunitoshi ^b   Kudo, Yoshio ^c   Nakajima, Teruo ^d   Nishimura, Tsuyoshi ^e   Saito, Masami ^f   Sakai, Toshiaki ^g   Yagi, Gohei ^h   Yamauchi, Toshio ⁱ  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c Haruki Hospital

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f KANSAI MEDICAL UNIVERSITY   (Japan)

^g OSAKA MEDICAL COLLEGE   (Japan)

^h KEIO UNIVERSITY   (Japan)

ⁱ SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Atypical antipsychotic; Clinical open label trial; Multi acting receptor targeted agent; Olanzapine; Schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; OLANZAPINE; PROLACTIN; TRIACYLGLYCEROL;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; PHASE 2 CLINICAL TRIAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; ANXIETY; BENZODIAZEPINES; FEMALE; HUMANS; JAPAN; MALE; MUSCLE RIGIDITY; PIRENZEPINE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; SLEEP DISORDERS; TREATMENT OUTCOME; TREMOR; TRIGLYCERIDES; WEIGHT GAIN;

EID: 0034892308     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2001.00875.x     Document Type: Article

References (19)

1. The pharmacology of olanzapine and other new antipsychotic agents
2. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
3. Multi-Acting Receptor Targeted Agent (MARTA)-dirty or rich?
4. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
5. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol
6. Phase I study of LY170053 (olanzapine): Single and multiple dose studies
7. Using the proportional odds model to asses the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial
8. Early phase 2 of risperidone, novel antipsychotic: High improvement rate and little extrapyramidal adverse reactions in schizophrenia
9. Late phase 2 study of risperidone in schizophrenia
10. Early Phase 2 study of a new antipsychotic. Perospirone HCl (SM-9018) on schizophrenia
11. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: Late-phase II study
12. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
13. Radioreceptor binding profile of the atypical antipsychotic olanzapine
14. Antipsychotic agents antagonize non-competitive N-methyl-D-asparate antagonist-induced behaviors
15. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity
16. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
17. Olanzapine versus placebo and halperidol: Acute phase results of the North American double-blind olanzapine trial
18. Review of the preclinical pharmacology of olanzapine; a MARTA class antipsychotic